{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:44:21Z","timestamp":1794005061171,"version":"4.8.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016304","name":"Medtronic Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neuromodulationjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromodulation: Technology at the Neural Interface"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.neurom.2022.03.003","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T16:58:56Z","timestamp":1649696336000},"page":"1126-1141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Effectiveness and Safety of Intrathecal Drug Delivery Systems for the Management of Cancer Pain: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-7415","authenticated-orcid":false,"given":"Rui","family":"Duarte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Copley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Nevitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Maden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Mohammed","family":"Al-Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Dupoiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Eldabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurom.2022.03.003_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.neurom.2022.03.003_bib2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/j.pain.0000000000001363","article-title":"The IASP classification of chronic pain for ICD-11: chronic cancer-related pain","volume":"160","author":"Bennett","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.neurom.2022.03.003_bib3","first-page":"3295","article-title":"Current perspectives on spinal cord stimulation for the treatment of cancer pain","volume":"13","author":"Hagedorn","year":"2020","journal-title":"J\u00a0Pain Res"},{"key":"10.1016\/j.neurom.2022.03.003_bib4","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdm056","article-title":"Prevalence of pain in patients with cancer: a systematic review of the past 40 years","volume":"18","author":"van den Beuken-van Everdingen","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.neurom.2022.03.003_bib5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0304-3959(01)00324-4","article-title":"Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology","volume":"93","author":"Meuser","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.neurom.2022.03.003_bib7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/ner.13264","article-title":"The unmet need for intrathecal drug delivery pumps for the treatment of cancer pain in England: an assessment of the hospital episode statistics database","volume":"23","author":"Duarte","year":"2020","journal-title":"Neuromodulation"},{"key":"10.1016\/j.neurom.2022.03.003_bib8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.36076\/ppj.2011\/14\/219","article-title":"Intrathecal therapy for cancer and non-cancer pain","volume":"14","author":"Hayek","year":"2011","journal-title":"Pain Physician"},{"key":"10.1016\/j.neurom.2022.03.003_bib9","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1093\/pm\/pnw060","article-title":"Intrathecal therapy for cancer-related pain","volume":"17","author":"Bruel","year":"2016","journal-title":"Pain Med"},{"key":"10.1016\/j.neurom.2022.03.003_bib10","first-page":"CD009389","article-title":"Spinal cord stimulation for cancer-related pain in adults","volume":"6","author":"Peng","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurom.2022.03.003_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11916-018-0662-z","article-title":"Intrathecal drug delivery and spinal cord stimulation for the treatment of cancer pain","volume":"22","author":"Xing","year":"2018","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.neurom.2022.03.003_bib12","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1097\/00000542-200406000-00034","article-title":"Prevention and management of intrathecal drug delivery and spinal cord stimulation system infections","volume":"100","author":"Follett","year":"2004","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neurom.2022.03.003_bib14","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.neurom.2022.03.003_bib15","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.neurom.2022.03.003_bib16","series-title":"Study quality assessment tools","year":"2014"},{"key":"10.1016\/j.neurom.2022.03.003_bib17","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1200\/JCO.2002.02.118","article-title":"Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival","volume":"20","author":"Smith","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.neurom.2022.03.003_bib18","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/annonc\/mdi156","article-title":"An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM)","volume":"16","author":"Smith","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.neurom.2022.03.003_bib19","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1089\/jpm.2005.8.736","article-title":"Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients","volume":"8","author":"Smith","year":"2005","journal-title":"J\u00a0Palliat Med"},{"key":"10.1016\/j.neurom.2022.03.003_bib20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/AAP.0000000000000251","article-title":"Prospective observational study of patient-controlled intrathecal analgesia: impact on cancer-associated symptoms, breakthrough pain control, and patient satisfaction","volume":"40","author":"Brogan","year":"2015","journal-title":"Reg Anesth Pain Med"},{"key":"10.1016\/j.neurom.2022.03.003_bib21","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1213\/ANE.0000000000004276","article-title":"Prospective association of serum opioid levels and clinical outcomes in patients with cancer pain treated With intrathecal opioid therapy","volume":"130","author":"Brogan","year":"2020","journal-title":"Anesth Analg"},{"key":"10.1016\/j.neurom.2022.03.003_bib22","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1213\/ANE.0000000000002903","article-title":"Intrathecal drug delivery systems for refractory pancreatic cancer pain: observational follow-up study over an 11-year period in a comprehensive cancer center","volume":"126","author":"Carvajal","year":"2018","journal-title":"Anesth Analg"},{"key":"10.1016\/j.neurom.2022.03.003_bib23","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.21037\/apm-20-1293","article-title":"Effects of family integrated care on refractory cancer-related pain receiving intrathecal morphine pump therapy: a cohort study","volume":"9","author":"Cheng","year":"2020","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.neurom.2022.03.003_bib24","first-page":"140","article-title":"Refractory cancer pain and intrathecal infusion: experience of three cancer management centers","volume":"12","author":"Dupoiron","year":"2011","journal-title":"Douleurs: Evaluation - Diagnostic - Traitement"},{"key":"10.1016\/j.neurom.2022.03.003_bib25","first-page":"441","article-title":"Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain","volume":"4","author":"Rauck","year":"2003","journal-title":"J\u00a0Pain"},{"key":"10.1016\/j.neurom.2022.03.003_bib26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1213\/ANE.0000000000004425","article-title":"Intrathecal drug delivery systems for cancer pain: an analysis of a prospective, multicenter product surveillance registry","volume":"130","author":"Stearns","year":"2020","journal-title":"Anesth Analg"},{"key":"10.1016\/j.neurom.2022.03.003_bib27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/1536867X1001000307","article-title":"Metaan: random-effects meta-analysis","volume":"10","author":"Kontopantelis","year":"2010","journal-title":"The Stata Journal"},{"key":"10.1016\/j.neurom.2022.03.003_bib28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/jrsm.1316","article-title":"A\u00a0comparison of heterogeneity variance estimators in simulated random-effects meta-analyses","volume":"10","author":"Langan","year":"2019","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.neurom.2022.03.003_bib29","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/j.1526-4637.2011.01262.x","article-title":"Patient-controlled intrathecal analgesia for the management of breakthrough cancer pain: a retrospective review and commentary","volume":"12","author":"Brogan","year":"2011","journal-title":"Pain Med"},{"key":"10.1016\/j.neurom.2022.03.003_bib30","unstructured":"Higgins JPT, Li T, Deeks JJ. Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, et\u00a0al, eds. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Cochrane; 2021."},{"key":"10.1016\/j.neurom.2022.03.003_bib31","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/ner.13161","article-title":"Evaluation of fixed intrathecal bupivacaine infusion doses in the oncologic population","volume":"23","author":"Chen","year":"2020","journal-title":"Neuromodulation"},{"key":"10.1016\/j.neurom.2022.03.003_bib32","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.neurom.2022.03.003_bib33","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00520-014-2219-y","article-title":"The association of presurgery psychological symptoms with postsurgery pain among cancer patients receiving implantable devices for pain management","volume":"22","author":"Aigner","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.neurom.2022.03.003_bib34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000048379","article-title":"The significance of intrathecal opioid therapy for the treatment of neuropathic cancer pain conditions","volume":"75","author":"Becker","year":"2000","journal-title":"Stereotact Funct Neurosurg"},{"key":"10.1016\/j.neurom.2022.03.003_bib35","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1093\/pm\/pnz096","article-title":"Optimizing initial intrathecal drug ratio for refractory cancer-related pain for early pain relief. A retrospective monocentric study","volume":"20","author":"Dupoiron","year":"2019","journal-title":"Pain Med"},{"key":"10.1016\/j.neurom.2022.03.003_bib36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.36076\/ppj.2013\/16\/251","article-title":"Infectious complications related to intrathecal drug delivery system and spinal cord stimulator system implantations at a comprehensive cancer pain center","volume":"16","author":"Engle","year":"2013","journal-title":"Pain Physician"},{"key":"10.1016\/j.neurom.2022.03.003_bib37","first-page":"161","article-title":"Intrathecal morphine delivered by implanted manual pump for cancer pain","volume":"6","author":"Erdine","year":"1996","journal-title":"Pain Digest"},{"key":"10.1016\/j.neurom.2022.03.003_bib38","first-page":"200","article-title":"Long-term pain relief produced by intrathecal morphine infusion in 53 patients","volume":"72","author":"Onofrio","year":"1990","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.neurom.2022.03.003_bib39","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1525-1403.2009.00206.x","article-title":"Continuous morphine infusion: a retrospective study of efficacy, safety, and demographic variables","volume":"12","author":"Reig","year":"2009","journal-title":"Neuromodulation"},{"key":"10.1016\/j.neurom.2022.03.003_bib40","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/ner.12759","article-title":"Retrospective analysis of intrathecal drug delivery: outcomes, efficacy, and risk for cancer-related pain at a high volume academic medical center","volume":"21","author":"Sayed","year":"2018","journal-title":"Neuromodulation"},{"key":"10.1016\/j.neurom.2022.03.003_bib41","first-page":"520","article-title":"Surgical site infections in cancer patients with intrathecal drug delivery devices","volume":"18","author":"Scanlon","year":"2017","journal-title":"Pain Medicine"},{"key":"10.1016\/j.neurom.2022.03.003_bib42","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/ner.13175","article-title":"Initiation of intrathecal drug delivery dramatically reduces systemic opioid use in patients with advanced cancer","volume":"23","author":"Sindt","year":"2020","journal-title":"Neuromodulation"},{"key":"10.1016\/j.neurom.2022.03.003_bib43","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1089\/jpm.2020.0206","article-title":"Evaluation of an intrathecal drug delivery protocol leads to rapid reduction of systemic opioids in the oncological population","volume":"24","author":"Spiegel","year":"2021","journal-title":"J\u00a0Palliat Med"},{"key":"10.1016\/j.neurom.2022.03.003_bib44","first-page":"13","article-title":"Implanted drug delivery systems for spinal administration of morphine in cancer pain relief","volume":"11","author":"Yegul","year":"1999","journal-title":"Agri-Istanbul"},{"key":"10.1016\/j.neurom.2022.03.003_bib45","first-page":"651","article-title":"Spinal cord stimulation for neuropathic pain: current perspectives","volume":"7","author":"Wolter","year":"2014","journal-title":"J\u00a0Pain Res"},{"key":"10.1016\/j.neurom.2022.03.003_bib46","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/ner.12208","article-title":"The appropriate use of neurostimulation of the spinal cord and peripheral nervous system for the treatment of chronic pain and ischemic diseases: the Neuromodulation Appropriateness Consensus Committee","volume":"17","author":"Deer","year":"2014","journal-title":"Neuromodulation"},{"key":"10.1016\/j.neurom.2022.03.003_bib47","first-page":"105","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"J\u00a0Pain"}],"container-title":["Neuromodulation: Technology at the Neural Interface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094715922005633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094715922005633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T06:51:41Z","timestamp":1691045501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094715922005633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1094715922005633"],"URL":"https:\/\/doi.org\/10.1016\/j.neurom.2022.03.003","relation":{},"ISSN":["1094-7159"],"issn-type":[{"value":"1094-7159","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and Safety of Intrathecal Drug Delivery Systems for the Management of Cancer Pain: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Neuromodulation: Technology at the Neural Interface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurom.2022.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the International Neuromodulation Society.","name":"copyright","label":"Copyright"}]}}